TICKERNERD
Menu
MGNXMGNXHealthcare · Biotechnology

MGNX Stock Forecast: MacroGenics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$4.10
+0.74% on the day

The 7 Wall Street analysts covering MacroGenics, Inc. hold a median 12-month price target of $7 — +70.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 67 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$261.2M
Ticker Nerd rank
67 / 100
Median analyst target
$7.00
Analysts covering
7
Total return, dividends reinvested
1W
−2.8%
1M
−9.7%
YTD
+154.7%
1Y
+184.7%
From 52W high
−15.6%
From 52W low
+208.3%
$1.33
$4.86
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MGNX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores MacroGenics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
67 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
95
Value
77
Size
65
Quality
60
Growth
58
Accruals
53
Revisions
48
Volatility
43
Issuance
23

Momentum (95): The shares have been drifting up relative to others.

Issuance (23): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MGNX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MGNX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Oct 25Jan 26Apr 26Jul 26MGNXHigh $11.00Median $7.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says7 analysts
3 Buy4 Hold0 Sell
Low $4.00Median $7.00High $11.00

The green dot is the last close — the median target sits +70.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 Aug 2026B. Riley SecuritiesMaintainsBuy—
17 Aug 2026B. Riley SecuritiesMaintainsBuy$9.00 → $11
20 Apr 2026BarclaysMaintainsOverweight—
20 Apr 2026BarclaysMaintainsOverweight$4.00 → $6.00
10 Apr 2026B. Riley SecuritiesUpgradeBuy—
10 Mar 2026BarclaysMaintainsOverweight—
3 Nov 2025HC Wainwright & Co.ReiteratesNeutral—
17 Sept 2025BarclaysAssumesOverweight$3.00
15 Aug 2025Leerink PartnersMaintainsOutperform—
20 May 2025B. Riley SecuritiesMaintainsNeutral—
14 May 2025BarclaysMaintainsOverweight—
14 May 2025StifelMaintainsHold—
25 Mar 2025HC Wainwright & Co.MaintainsNeutral—
7 Nov 2024JMP SecuritiesDowngradeMarket Perform—
6 Nov 2024HC Wainwright & Co.ReiteratesNeutral—
18 Sept 2024HC Wainwright & Co.ReiteratesNeutral—
21 Aug 2024HC Wainwright & Co.ReiteratesNeutral—
15 Aug 2024CitigroupMaintainsBuy—
7 Aug 2024BMO CapitalMaintainsMarket Perform—
1 Aug 2024BTIGDowngradeNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MGNX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

MGNX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

MacroGenics, Inc. (MGNX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
25.3×

Cheaper than 31% of US stocks

Price / sales
1.5×

Cheaper than 61% of US stocks

Price / book
6.1×

Cheaper than 18% of US stocks

EV / EBITDA
−3.8×

Cheaper than 76% of US stocks

Growth & margins
Revenue growth (YoY)
378.0%

Higher than 98% of US stocks

Earnings growth (YoY)
57.5%

Higher than 77% of US stocks

Gross margin
54.1%

Higher than 67% of US stocks

Operating margin
−42.2%

Higher than 18% of US stocks

Net margin
−8.3%

Higher than 21% of US stocks

Returns & dividend
Return on equity
−225.8%

Higher than 6% of US stocks

Return on assets
−8.1%

Higher than 28% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

MGNX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MGNXMacroGenics, Inc.$261.2M
67
ALECAlector, Inc.$257.6M
42
PYXSPyxis Oncology, Inc.$256.9M
80
SLGLSol-Gel Technologies Ltd.$254.1M
45
NAGENiagen Bioscience, Inc.$254.0M
54
LCTXLineage Cell Therapeutics, Inc.$269.0M
56
WHWKWhitehawk Therapeutics, Inc.$269.7M
73

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own MacroGenics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MGNX news & analysis

Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?

Zacks Investment Research · 20 Aug 2026neutral

The article compares MacroGenics (MGNX) and CareDx (CDNA) stock performance so far this year relative to their medical-sector peers. The headline poses the question of whether MGNX is outpacing its medical peers, addressing the stock's year-to-date performance within its sector.

Why it matters — MGNX watchers would care because the comparison indicates where the company's stock currently stands against its sector peers this year, signaling its relative performance in the market.

MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research · 13 Aug 2026positive

MacroGenics reported a Q2 loss of $0.27 per share, which was narrower than the Zacks Consensus Estimate of a $0.40 loss and improved from the $0.57 loss in the year-ago quarter. The company's quarterly results lagged revenue estimates.

Why it matters — MGNX watchers would note that the company's per-share loss narrowed significantly versus both analyst expectations and the prior-year quarter, even as revenue came up short of estimates.

MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position

GlobeNewsWire · 13 Aug 2026positive

MacroGenics reported its financial results for the quarter ended June 30, 2026, and highlighted recent corporate and pipeline progress. The headline notes a streamlined operating model and strengthened financial position.

Why it matters — The update offers MGNX watchers an overview of the company's operational and financial standing as it continues advancing its antibody-based cancer therapeutics pipeline.

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise of Option to License Preclinical Bispecific Program

GlobeNewsWire · 11 Aug 2026positive

Gilead Sciences exercised its option under a 2022 collaboration agreement to obtain an exclusive license for a preclinical bispecific program from MacroGenics, triggering a $10 million payment to MacroGenics. The announcement was made by MacroGenics on Aug. 11, 2026.

Why it matters — This option exercise results in a $10 million milestone payment to MacroGenics and progresses the companies' collaboration on a preclinical bispecific program.

MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still Important

Seeking Alpha · 27 July 2026positive

The article reaffirms a 'Buy' rating on MacroGenics, citing a de-risked operational runway through 2028 and a promising B7-H3 ADC pipeline asset, MGC026, which shows no major safety issues and is expected to have data readout in late 2026.

Why it matters — MGNX watchers would care because the extended cash runway and refocused pipeline, particularly the upcoming MGC026 data in late 2026, represent key milestones that could drive significant upside for the company.

FAQ

Frequently asked questions about MGNX stock

What is the MGNX stock price forecast for 2026-2027?

The 7 Wall Street analysts covering MacroGenics, Inc. have a median 12-month price target of $7, with estimates ranging from $4 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MGNX stock a buy right now?

Of the 7 analysts covering MacroGenics, Inc., 3 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MacroGenics, Inc. 67 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MGNX?

As at 22 Aug 2026, MacroGenics, Inc. ranks 67 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (95 of 100).

Will MGNX stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +70.7% from the last close, and Ticker Nerd's factor model ranks MacroGenics, Inc. 67 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MGNX stock forecast for 2030?

No analyst covering MacroGenics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MGNX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $11 over the next 12 months.

How has MGNX stock performed over the past year?

MacroGenics, Inc. returned +184.7% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does MacroGenics, Inc. do?

MacroGenics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing antibody-based therapeutics primarily for cancer treatment.

What is the latest news on MGNX?

The most recent item we track (Zacks Investment Research, 20 Aug 2026): "Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?". The article compares MacroGenics (MGNX) and CareDx (CDNA) stock performance so far this year relative to their medical-sector peers. The headline poses the question of whether MGNX is outpacing its medical peers, addressing the stock's year-to-date performance within its sector.

Company

About MacroGenics, Inc.

MacroGenics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing antibody-based therapeutics primarily for cancer treatment. Its approved product, MARGENZA (margetuximab-cmkb), targets HER2-positive metastatic breast cancer in adult patients who have received prior anti-HER2 therapies. The company's robust pipeline features innovative candidates leveraging proprietary DART (Dual-Affinity Re-Targeting) molecules and antibody-drug conjugates (ADCs). Key investigational assets include lorigerlimab, a bispecific DART targeting PD-1 and CTLA-4 checkpoints; MGC026, an ADC against B7-H3 with a novel topoisomerase I inhibitor payload; and MGC028, targeting ADAM9 with a similar advanced payload technology. Additional pipeline products address various tumor-associated antigens and immune checkpoints. MacroGenics Inc. operates in the competitive oncology sector, advancing precision therapies to modulate immune responses and deliver targeted cytotoxicity. Founded in 2000 and headquartered in Rockville, Maryland, it plays a vital role in the biotechnology landscape by pushing boundaries in immuno-oncology and ADC innovations.

CEO Mr. Eric Blasius Risser · 293 employees · United States · https://www.macrogenics.com